B. Metzler seel. Sohn & Co. AG Reduces Stake in Labcorp Holdings Inc. $LH

Key Points

• B. Metzler seel. Sohn & Co. AG reduced its holdings in Labcorp by 28.1%, now owning 3,175 shares valued at approximately $739,000.
• Labcorp's earnings per share (EPS) for the last quarter was reported at $4.35, exceeding analysts' expectations of $4.14, alongside a revenue increase of 9.6% year-over-year.
• The company declared a quarterly dividend of $0.72 per share, with a dividend yield of 1.0% and a payout ratio of 31.79%.

B. Metzler seel. Sohn & Co. AG decreased its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 28.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,175 shares of the medical research company's stock after selling 1,241 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Labcorp were worth $739,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in LH. Golden State Wealth Management LLC grew its position in shares of Labcorp by 88.1% in the first quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company's stock valued at $26,000 after purchasing an additional 52 shares in the last quarter. North Capital Inc. purchased a new position in shares of Labcorp in the first quarter valued at $27,000. TruNorth Capital Management LLC purchased a new position in Labcorp during the first quarter valued at approximately $28,000. Larson Financial Group LLC grew its stake in Labcorp by 140.4% during the first quarter. Larson Financial Group LLC now owns 125 shares of the medical research company's stock valued at $29,000 after acquiring an additional 73 shares in the last quarter. Finally, Financial Gravity Asset Management Inc. purchased a new position in Labcorp during the first quarter valued at approximately $31,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. UBS Group boosted their price objective on shares of Labcorp from $282.00 to $305.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Truist Financial boosted their target price on Labcorp from $290.00 to $310.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Evercore ISI boosted their target price on Labcorp from $285.00 to $300.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Morgan Stanley boosted their target price on Labcorp from $283.00 to $306.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Finally, Robert W. Baird set a $311.00 target price on Labcorp in a research report on Monday, August 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $290.33.

Labcorp Trading Up 0.1%

Shares of Labcorp stock traded up $0.38 during trading on Thursday, reaching $274.22. The company's stock had a trading volume of 141,701 shares, compared to its average volume of 703,240. Labcorp Holdings Inc. has a 52-week low of $209.38 and a 52-week high of $283.47. The company has a market cap of $22.79 billion, a price-to-earnings ratio of 30.27, a PEG ratio of 1.78 and a beta of 0.85. The firm's 50-day moving average is $263.61 and its two-hundred day moving average is $249.77. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.61.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $4.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.14 by $0.21. Labcorp had a net margin of 5.66% and a return on equity of 15.45%. The company had revenue of $3.53 billion during the quarter, compared to analysts' expectations of $3.49 billion. During the same quarter in the prior year, the company earned $3.94 EPS. The firm's revenue was up 9.6% on a year-over-year basis. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. On average, sell-side analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Thursday, August 28th will be issued a dividend of $0.72 per share. The ex-dividend date is Thursday, August 28th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp's dividend payout ratio is currently 31.79%.

Insider Buying and Selling

In other Labcorp news, Director Kerrii B. Anderson sold 3,500 shares of the stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $280.00, for a total transaction of $980,000.00. Following the completion of the sale, the director owned 8,666 shares of the company's stock, valued at $2,426,480. This represents a 28.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Der Vaart Sandra D. Van sold 3,903 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total transaction of $1,059,352.26. Following the sale, the executive vice president directly owned 2,274 shares of the company's stock, valued at $617,209.08. The trade was a 63.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,046 shares of company stock valued at $4,337,192. 0.84% of the stock is owned by insiders.

Labcorp Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.